U.S. markets open in 7 hours 27 minutes


Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
12.40-0.35 (-2.75%)
At close: 5:14PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close12.75
Bid0.00 x 0
Ask0.00 x 0
Day's Range12.00 - 12.70
52 Week Range8.65 - 15.55
Avg. Volume2,411
Market Cap170.397M
Beta (5Y Monthly)0.62
PE Ratio (TTM)N/A
EPS (TTM)-1.05
Earnings DateSep 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 03, 2017
1y Target Est14.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      PCAS: 1st Half 2021 earnings report

      Ecully, September 9, 2021 1st HALF 2021 EARNINGS REPORT PCAS (Euronext Paris: PCA), a specialist in the development and production of complex molecules for life sciences and innovative technologies, announces the publication of its consolidated earnings for the first half of 2021. in millions of euros 30 June 2020 30 June 2021 Net sales 105.1 106.3 EBITDA (*) 7.2 8.0 EBITDA margin 6.9% 7.5% Current operating income (*) -3.0 -2.6 Other operating income and expenses -0.2 -0.4 Operating income -3.2

    • GlobeNewswire

      PCAS: H1 2021 Net Sales

      Ecully, July 21, 2021 H1 2021 NET SALES PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of June 30, 2021. The PCAS Group had generated consolidated net sales of €106.3 million as of June 30, 2021, up 1.1% compared to the same period in the previous financial year (+3.1% at a constant exchange rate). In millions of euros 2021 2020 % change 2021 At a

    • GlobeNewswire

      PCAS: release of the 2020 Universal Registration Document

      RELEASE OF THE 2020 UNIVERSAL REGISTRATION DOCUMENT (URD) Ecully, May 5, 2021 The PCAS Universal Registration Document 2020, which includes the annual financial report, was filed with France's Financial Markets Authority on May 5, 2021, under number D.21-0429. This document contains: The 2020 annual financial reportThe Board of Directors' corporate governance report in accordance with Section L.225-37 of France's Commercial CodeInformation on the statutory auditors' fees This document is now available: At PCAS headquarters: 21 chemin de la Sauvegarde, 21 Ecully Parc, CS 33167, 69134 Ecully, FranceOn the company website: www.pcas.com NEXT FINANCIAL DISCLOSURE:2020 Shareholder’s Meeting in Ecully at 10 a.m. on June 9, 2021 ABOUT PCAS PCAS specializes in the development and production of complex molecules for life sciences and innovative technologies. With 10% of its net sales earmarked for R&D and a large international footprint, PCAS is the preferred industrial partner for market-leading major global groups. Boasting especially high standards, the company offers a growing range of proprietary products and solutions in leading-edge segments. PCAS generated net sales of €194.1 million in 2020 and employs close to 1 100 people in six countries. To find out more about PCAS: www.pcas.com PCASNewcapPierre Luzeau / Eric MoissenotEmmanuel Huynh / Louis-Victor DelouvrierFinancial communication and investor relationsTél. : +33 1 69 79 60 00 www.pcas.comTél. : +33 1 44 71 98 53pcas@newcap.eu Attachment PCAS - REL_URD_2020